V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Incyte Executive Compensation (FY25)

INCY · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): June 9, 2026
402 figures on this page: 394 cited to the filing that reported them, 8 calculated from figures it prints. See the citations
Total compensation for William Meury, Chief Executive Officer, came to $32,085,952 in fiscal 2025, and for fiscal 2025, the company reported a chief executive pay ratio of 110.5:1, against median employee compensation of $295,914. Meanwhile, for fiscal 2025, shareholders backed the say-on-pay proposal with 83.9% of votes cast for or against in favor at the meeting held June 8, 2026. Separately, the disclosed peer group names Alnylam Pharmaceuticals, Inc., argenx SE, BeOne Medicines Ltd., Biogen Inc. and BioMarin Pharmaceutical Inc., among others. The fiscal 2025 disclosure covers 7 named executive officers.
Chief executive, fiscal 2025
◇
William Meury
Median of the other named officers
$6,342,349
6 officers, excluding the chief executive
Latest say-on-pay support
=
June 8, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive of record: Herve Hoppenot → William Meury
Say-on-pay support: 92.2% → 83.9% (8.3 points lower)
CEO pay ratio: 68:1 → 110.5:1 (62.5% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Incyte's chief executive and what were they paid?
Total compensation for William Meury, Chief Executive Officer, came to $32,085,952 in fiscal 2025.
What was Incyte's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 83.9% of votes cast for or against in favor at the meeting held June 8, 2026.
Which companies are in Incyte's peer group?
The disclosed peer group names Alnylam Pharmaceuticals, Inc., argenx SE, BeOne Medicines Ltd., Biogen Inc. and BioMarin Pharmaceutical Inc., among others.
What is Incyte's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 110.5:1, against median employee compensation of $295,914.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Herve Hoppenot
Chief Executive Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Herve Hoppenot
Chief Executive Officer
◇—◇◇◇—◇◇
Barry Flannelly
Executive Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Herve Hoppenot
Chief Executive Officer
◇—◇◇◇—◇◇
Steven Stein
Executive Vice President and Chief Medical Officer, Oncology
◇—◇◇◇—◇◇
Barry Flannelly
Executive Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
William Meury
Chief Executive Officer
◇—◇◇◇—◇◇
Mohamed Issa
Executive Vice President and Head of U.S. Commercial
◇◇◇◇◇—◇◇
Pablo Cagnoni
President and Global Head of Research and Development
◇—◇◇◇—◇◇
Herve Hoppenot
Former President and Chief Executive Officer
Departed during or after this year
◇—◇◇◇—◇◇
Steven Stein
Executive Vice President, Chief Medical Officer and Head of Late-stage Development
◇—◇◇◇—◇◇
Christiana Stamoulis
Former Executive Vice President and Chief Financial Officer
Departed during or after this year
◇—◇◇——◇◇
Thomas Tray
Vice President, Chief Accounting Officer and Principal Financial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Christiana StamoulisPSU◇—◇—◇—◇
Christiana StamoulisPSU◇◇◇—◇—◇
Christiana StamoulisOPTION◇——◇—◇◇
Christiana StamoulisOPTION◇——◇—◇◇
Herv HoppenotPSU◇◇◇—◇—◇
Herv HoppenotOPTION◇——◇—◇◇
Herv HoppenotOPTION◇——◇—◇◇
Herv HoppenotPSU◇—◇—◇—◇
Herv HoppenotOPTION◇——◇—◇◇
Mohamed IssaPSU◇—◇—◇—◇
Mohamed IssaRSU◇——◇——◇
Mohamed IssaPSU◇◇◇—◇—◇
Mohamed IssaPSU◇—◇—◇—◇
Mohamed IssaOPTION◇——◇—◇◇
Pablo J. CagnoniPSU◇◇◇—◇—◇
Pablo J. CagnoniOPTION◇——◇—◇◇
Pablo J. CagnoniOPTION◇——◇—◇◇
Pablo J. CagnoniPSU◇—◇—◇—◇
Steven H. SteinPSU◇◇◇—◇—◇
Steven H. SteinPSU◇—◇—◇—◇
Steven H. SteinOPTION◇——◇—◇◇
Steven H. SteinOPTION◇——◇—◇◇
Thomas TrayOPTION◇——◇—◇◇
Thomas TrayPSU◇—◇—◇—◇
Thomas TrayOPTION◇——◇—◇◇
William J. MeuryOPTION◇——◇—◇◇
William J. MeuryRSU◇——◇——◇
William J. MeuryPSU◇◇◇—◇—◇
William J. MeuryPSU◇—◇—◇—◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
William MeuryOption◇—◇06/25/2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
Steven SteinOption◇—◇01/16/2035
RSU◇◇——
Option◇—◇07/14/2034
RSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇07/13/2033
Option◇—◇01/19/2033
Option◇—◇07/01/2032
RSU◇◇——
RSU◇◇——
Option◇—◇07/14/2035
RSU◇◇——
Option◇—◇01/17/2034
RSU◇◇——
RSU◇◇——
Thomas TrayOption◇—◇07/14/2035
RSU◇◇——
Option◇—◇01/17/2034
RSU◇◇——
Option◇—◇07/14/2034
RSU◇◇——
RSU◇◇——
Option◇—◇07/01/2032
Option◇—◇01/16/2035
Option◇—◇01/19/2033
Option◇—◇07/14/2033
RSU◇◇——
Mohamed IssaRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇07/14/2035
RSU◇◇——
Hervé HoppenotOption◇—◇07/01/2032
Option◇—◇01/16/2035
Option◇—◇01/19/2033
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇01/17/2034
RSU◇◇——
Option◇—◇07/13/2033
RSU◇◇——
Option◇—◇06/25/2035
Option◇—◇07/14/2034
RSU◇◇——
Pablo CagnoniOption◇—◇07/14/2034
RSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇01/17/2034
Option◇—◇01/16/2035
Option◇—◇07/14/2035
RSU◇◇——
RSU◇◇——
Option◇—◇07/13/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Julian C. Baker
Board chair
—◇◇———◇
Edmund P. Harrigan
—◇◇———◇
Paul J. Clancy
—◇◇———◇
Jacqualyn A. Fouse
◇◇◇———◇
Susanne Schaffert
◇◇◇———◇
Katherine A. High
◇◇◇———◇
Otis W. Brawley
◇◇◇———◇
Herve Hoppenot, William J. Meury and Jean-Jacques Bienaim served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as 60% Options / 40% RSUs.
Stock ownership guideline: 6x Annual Cash Retainer

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Alnylam Pharmaceuticals, Inc. ALNY
  • argenx SE ARGX
  • BeOne Medicines Ltd. ONC
  • Biogen Inc. BIIB
  • BioMarin Pharmaceutical Inc. BMRN
  • Exelixis, Inc. EXEL
  • Genmab A/S GMAB
  • Illumina, Inc. ILMN
  • Jazz Pharmaceuticals plc JAZZ
  • Moderna, Inc. MRNA
  • Natera, Inc. NTRA
  • Neurocrine Biosciences, Inc. NBIX
  • PTC Therapeutics, Inc. PTCT
  • United Therapeutics Corporation UTHR

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 8, 2026=◇◇◇
2024April 11, 2025=◇◇◇
2023June 12, 2024=◇◇◇
2022June 14, 2023=◇◇◇
2021June 15, 2022=◇◇◇
2020May 13, 2021=◇◇◇
2019May 26, 2020=◇◇◇
2018April 26, 2019=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Incyte files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Incyte disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Incyte sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Incyte's disclosed peer group is defensible, who names Incyte back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
402 figures on this page: 394 cited to the filing that reported them, 8 calculated from figures it prints.
394 cited to the filing
8 calculated from the filing

Documents cited

  1. 0000879169-26-000043
  2. 0000879169-26-000031
    2025 NON-EMPLOYEE DIRECTOR COMPENSATION TABLE · 2025 Outstanding Equity Awards at Fiscal Year-End · CEO Pay Ratio · Director Compensation · and 2 more sections
  3. 0000879169-25-000062
  4. 0001104659-25-041209
    Executive Compensation Tables
  5. 0000879169-24-000082
  6. 0001104659-24-053517
    Executive Compensation Tables · Summary Compensation Table
  7. 0001104659-23-071561
  8. 0001104659-23-052109
    Summary Compensation Table
  9. 0001104659-22-071867
  10. 0001104659-21-073209
  11. 0001104659-20-066387
  12. 0001104659-19-025327
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Incyte executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/INCY (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Incyte and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Incyte discloses

The companies named in INCY's own disclosed peer group.

Alnylam Pharmaceuticals, Inc.Biogen Inc.BioMarin Pharmaceutical Inc.Exelixis, Inc.Illumina, Inc.Jazz Pharmaceuticals plcModerna, Inc.Neurocrine Biosciences, Inc.PTC Therapeutics, Inc.United Therapeutics Corporation

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy